share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K：重大事件
美股SEC公告 ·  2024/09/09 21:05

Moomoo AI 已提取核心信息

At the 2024 Annual Meeting on September 3, Allarity Therapeutics' stockholders approved multiple significant corporate actions. The company will implement a 1-for-30 reverse stock split effective September 11, 2024, with fractional shares being rounded up to the next whole number. The stock will continue trading under the symbol "ALLR" on Nasdaq with a new CUSIP number.Stockholders also approved reducing the total authorized shares from 750.5 million to 250.5 million, with common stock authorization decreasing from 750 million to 250 million shares. Additionally, the company's 2021 Equity Incentive Plan was amended to increase the authorized shares from 2.17 million to 10.59 million.Other approved measures included the election of two Class II directors, ratification of Wolf & Company as the independent auditor, and an amendment to limit certain officers' liability under Delaware law. All seven proposals presented at the meeting received sufficient stockholder approval.
At the 2024 Annual Meeting on September 3, Allarity Therapeutics' stockholders approved multiple significant corporate actions. The company will implement a 1-for-30 reverse stock split effective September 11, 2024, with fractional shares being rounded up to the next whole number. The stock will continue trading under the symbol "ALLR" on Nasdaq with a new CUSIP number.Stockholders also approved reducing the total authorized shares from 750.5 million to 250.5 million, with common stock authorization decreasing from 750 million to 250 million shares. Additionally, the company's 2021 Equity Incentive Plan was amended to increase the authorized shares from 2.17 million to 10.59 million.Other approved measures included the election of two Class II directors, ratification of Wolf & Company as the independent auditor, and an amendment to limit certain officers' liability under Delaware law. All seven proposals presented at the meeting received sufficient stockholder approval.
在2024年9月3日的年度会议上，Allarity Therapeutics的股东批准了多项重要的公司行动。公司将于2024年9月11日实施1拆30的反向股票分割，碎股将向上舍入至下一个整数。股票将继续在纳斯达克交易，标的为"ALLR"，并将使用新的CUSIP号码。股东们还批准了将授权的总股份从75050万减少到25050万，其中普通股的授权从75000万减少到25000万股。此外，该公司的2021年股权激励计划也进行了修订，授权股份从217万增加到1059万。其他批准的措施包括选举两名二级董事，确认Wolf & Company为独立审计师，以及修订以限制某些官员在特拉华州法律下的责任。会议上提出的所有七项提案都获得了足够的股东批准。
在2024年9月3日的年度会议上，Allarity Therapeutics的股东批准了多项重要的公司行动。公司将于2024年9月11日实施1拆30的反向股票分割，碎股将向上舍入至下一个整数。股票将继续在纳斯达克交易，标的为"ALLR"，并将使用新的CUSIP号码。股东们还批准了将授权的总股份从75050万减少到25050万，其中普通股的授权从75000万减少到25000万股。此外，该公司的2021年股权激励计划也进行了修订，授权股份从217万增加到1059万。其他批准的措施包括选举两名二级董事，确认Wolf & Company为独立审计师，以及修订以限制某些官员在特拉华州法律下的责任。会议上提出的所有七项提案都获得了足够的股东批准。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Forte Biosciences
    FBRX
    -- 8.510
    Plus Therapeutics
    PSTV
    -- 1.4300
    IO Biotech
    IOBT
    -- 1.170
    Celularity
    CELU
    -- 2.1500
    Tiziana Life Sciences
    TLSA
    -- 1.2300
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点